NEW YORK (GenomeWeb) – Molecular diagnostics developer CombiMatrix announced today that it has priced an underwritten public offering of 8,000 units of Series F convertible preferred stock and warrants at $1,000 per unit.

The firm hopes to raise gross proceeds of $8 million, part of which it will use to repurchase and retire its Series E convertible preferred stock. The offering is expected to close on or about March 24. Ladenburg Thalmann & Co. served as the sole bookrunning manager and Aegis Capital served as lead manager for the transaction.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.